Innovative Technologies for Patients with Heart Valve Disease
The tricuspid regurgitation (TR) and mitral regurgitation (MR) markets are underserved, with inadequate treatment options available today. Our innovative, IP-protected portfolio and pipeline of minimally invasive devices increase ease of use and patient accessibility to life-saving care.
TricValve®
TricValve® – Transcatheter Bicaval Valves System is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. It is intended for patients with severe TR at high risk or who are inoperable for open surgical therapy.
Vienna Aortic Valve SE
The Vienna Aortic Valve SE – Self-expandable Transcatheter Valve System is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery. The minimally invasive heart valve replaces the native valve without the need for concomitant surgical removal and is placed through femoral access. The new generation device comes fully premounted with specially prepared bovine pericardium, thus reducing preparation steps and procedure time.
Munich Transcatheter Mitral Valve System
The Mitral Valve is designed to treat mitral regurgitation. It comprises an anchoring system and hooks to block the native valve in the proper positioning. This system is intended for use in adult patients suffering from heart failure symptoms (NYHA class II or greater) with moderate or severe MR who are deemed to be at high risk for surgical valve repair or replacement, as confirmed by a Heart Team that includes at least a cardiac surgeon and a cardiologist.
Perspective Transcatheter Pulmonary Valve
This device is designed to treat pulmonary regurgitation in infants with this congenital defect. It can target a niche market, especially in countries without pre-natal screenings.